518 related articles for article (PubMed ID: 16415489)
1. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
Chłopicki S; Gryglewski RJ
Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
Tschudi MR; Noll G; Lüscher TP
Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
[TBL] [Abstract][Full Text] [Related]
3. The possible therapeutic actions of peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, PPAR gamma agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium (Ca)-antagonists on vascular endothelial cells.
Inoue I; Katayama S
Curr Drug Targets Cardiovasc Haematol Disord; 2004 Mar; 4(1):35-52. PubMed ID: 15032651
[TBL] [Abstract][Full Text] [Related]
4. Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins.
Gryglewski RJ; Uracz W; Swies J; Chlopicki S; Marcinkiewicz E; Lomnicka M; Madej J
Ann N Y Acad Sci; 2001 Dec; 947():229-45; discussion 245-6. PubMed ID: 11795271
[TBL] [Abstract][Full Text] [Related]
5. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
6. ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles.
Tiefenbacher CP; Friedrich S; Bleeke T; Vahl C; Chen X; Niroomand F
Am J Physiol Heart Circ Physiol; 2004 Apr; 286(4):H1425-32. PubMed ID: 14644762
[TBL] [Abstract][Full Text] [Related]
7. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
Enseleit F; Hürlimann D; Lüscher TF
J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
[TBL] [Abstract][Full Text] [Related]
8. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
9. Current pharmacological approach to restore endothelial dysfunction.
Dobarro D; Gómez-Rubín MC; Sanchez-Recalde A; Moreno R; Galeote G; Jimenez-Valero S; Calvo L; López de Sá E; López-Sendón JL
Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):212-22. PubMed ID: 19689260
[TBL] [Abstract][Full Text] [Related]
10. The effects of HMG-CoA reductase inhibitors on endothelial function.
Tesfamariam B
Am J Cardiovasc Drugs; 2006; 6(2):115-20. PubMed ID: 16555864
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study.
Ruszkowski P; Masajtis-Zagajewska A; Nowicki M
J Renin Angiotensin Aldosterone Syst; 2019; 20(3):1470320319868890. PubMed ID: 31486700
[TBL] [Abstract][Full Text] [Related]
12. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR; Kanwar YS
FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of HMG-CoA reductase inhibitors.
Bocan TM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
[TBL] [Abstract][Full Text] [Related]
14. Restoring the dysfunctional endothelium.
Osto E; Coppolino G; Volpe M; Cosentino F
Curr Pharm Des; 2007; 13(10):1053-68. PubMed ID: 17430168
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of vascular endothelium. Delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.
Gryglewski RJ
FEBS J; 2005 Jun; 272(12):2956-67. PubMed ID: 15955056
[TBL] [Abstract][Full Text] [Related]
16. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
Pitt B
Am J Cardiol; 1997 Mar; 79(5A):24-8. PubMed ID: 9127618
[TBL] [Abstract][Full Text] [Related]
17. How do HMG-CoA reductase inhibitors prevent stroke?
Bedi A; Flaker GC
Am J Cardiovasc Drugs; 2002; 2(1):7-14. PubMed ID: 14727994
[TBL] [Abstract][Full Text] [Related]
18. Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?
Ruland S; Gorelick PB
Curr Atheroscler Rep; 2003 Jan; 5(1):38-43. PubMed ID: 12562541
[TBL] [Abstract][Full Text] [Related]
19. [New possibilities in the pharmacologic prevention of age-related macular degeneration].
Fischer T
Orv Hetil; 2008 Jan; 149(3):121-7. PubMed ID: 18194920
[TBL] [Abstract][Full Text] [Related]
20. Endothelial function and the kidney. An emerging target for cardiovascular therapy.
Rabelink TJ; Koomans HA
Drugs; 1997; 53 Suppl 1():11-9. PubMed ID: 9034751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
